Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells
about
CD4+ T Cells Targeting Dominant and Cryptic Epitopes from Bacillus anthracis Lethal FactorLong peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.Immunization with different formulations of Mycobacterium tuberculosis antigen 85A induces immune responses with different specificity and protective efficacy.T cell responses to viral infections - opportunities for Peptide vaccination.Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.Vaccines for established cancer: overcoming the challenges posed by immune evasion.Spatial separation of the processing and MHC class I loading compartments for cross-presentation of the tumor-associated antigen HER2/neu by human dendritic cells.Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles.ML1419c peptide immunization induces Mycobacterium leprae-specific HLA-A*0201-restricted CTL in vivo with potential to kill live mycobacteria.Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins.Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell Immunity.Harnessing Invariant NKT Cells to Improve Influenza Vaccines: A Pig Perspective.Therapeutic cancer vaccines.Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.Vaccination of koalas (Phascolarctos cinereus) against Chlamydia pecorum using synthetic peptides derived from the major outer membrane protein.
P2860
Q28383022-B667F37A-3C07-4DB9-813D-F56E3EF1B88CQ33578049-9C6890FA-69FB-4020-B261-DA777DBBF43DQ37503926-E83F71B8-B263-453E-9DB4-493A66E22BBEQ37718978-39919849-4BDD-42DE-BE3F-1320AA15B631Q38758254-4EA691C2-2E11-420F-A146-60559134A172Q38769021-4DBDDD8E-089E-467F-8B55-EEE146513E0FQ39014554-EF6E1EC8-0EA4-4FE8-BD13-E7AC635B4EB9Q39049093-63E666DA-5414-436D-AC37-E45FD49714B9Q39161562-B66A860D-13FD-4D78-B447-D6A983A06A60Q42220548-FBFFC9B4-7D88-488A-B6D6-44CDF7602B04Q42938763-866AF31D-06D7-43A3-888A-8B49AB6D078FQ47548620-5D4BE5B7-7286-4F57-B82C-8D527185002AQ48343602-019A23FF-C5BA-46EA-8082-891E1D810CC9Q50988785-605E968B-E9A3-4C65-912E-209F844CE241Q54961397-B0F9331A-B357-4725-B89B-2634B0B5AD82Q55472927-1CB6908A-3342-4157-8018-633EF3F32414
P2860
Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparing pooled peptides with ...... otective CD8+ and CD4+ T cells
@en
Comparing pooled peptides with ...... tective CD8+ and CD4+ T cells.
@nl
type
label
Comparing pooled peptides with ...... otective CD8+ and CD4+ T cells
@en
Comparing pooled peptides with ...... tective CD8+ and CD4+ T cells.
@nl
prefLabel
Comparing pooled peptides with ...... otective CD8+ and CD4+ T cells
@en
Comparing pooled peptides with ...... tective CD8+ and CD4+ T cells.
@nl
P2093
P2860
P356
P1476
Comparing pooled peptides with ...... otective CD8+ and CD4+ T cells
@en
P2093
Adam Stoten
Andrew McMichael
Hongwei Zhang
Katalin Di Gleria
Shisong Jiang
Xiao-Ning Xu
P2860
P304
P356
10.1074/JBC.M809456200
P407
P577
2009-02-04T00:00:00Z